SRXN1 and hepatocellular carcinoma: SRXN1 enhances hepatocellular carcinoma progression by modulating lysosome biogenesis and autophagic flux, with its inhibition showing synergistic antitumor effects with sorafenib by increasing ROS levels, positioning it as a potential therapeutic target for HCC.